CAMELA, ELISA
 Distribuzione geografica
Continente #
AS - Asia 1.653
EU - Europa 1.300
NA - Nord America 1.272
SA - Sud America 216
AF - Africa 59
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 4.507
Nazione #
US - Stati Uniti d'America 1.231
SG - Singapore 849
RU - Federazione Russa 757
CN - Cina 344
HK - Hong Kong 207
BR - Brasile 185
DE - Germania 156
IT - Italia 124
VN - Vietnam 86
IN - India 72
FR - Francia 50
NL - Olanda 48
GB - Regno Unito 39
KR - Corea 28
UA - Ucraina 28
CI - Costa d'Avorio 24
FI - Finlandia 21
CA - Canada 20
ZA - Sudafrica 15
SE - Svezia 13
MX - Messico 12
PL - Polonia 12
BG - Bulgaria 10
TR - Turchia 10
BD - Bangladesh 9
IE - Irlanda 9
JP - Giappone 9
AR - Argentina 8
EC - Ecuador 7
ID - Indonesia 7
ES - Italia 6
VE - Venezuela 6
LT - Lituania 5
RS - Serbia 5
AZ - Azerbaigian 3
CO - Colombia 3
JO - Giordania 3
LB - Libano 3
PE - Perù 3
RO - Romania 3
SN - Senegal 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
AU - Australia 2
CH - Svizzera 2
CR - Costa Rica 2
HN - Honduras 2
HU - Ungheria 2
IQ - Iraq 2
IR - Iran 2
MA - Marocco 2
NP - Nepal 2
PY - Paraguay 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
CG - Congo 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
GM - Gambi 1
GN - Guinea 1
GR - Grecia 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
ML - Mali 1
NC - Nuova Caledonia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PS - Palestinian Territory 1
PT - Portogallo 1
SA - Arabia Saudita 1
SD - Sudan 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
YT - Mayotte 1
ZW - Zimbabwe 1
Totale 4.507
Città #
Singapore 379
Hong Kong 202
Ashburn 189
Moscow 177
Chandler 150
Hefei 126
Beijing 104
Santa Clara 97
Los Angeles 46
Ho Chi Minh City 36
Amsterdam 35
Lawrence 32
Napoli 31
Millbury 26
Seoul 25
Boston 22
Munich 22
Seattle 22
São Paulo 22
Naples 21
Buffalo 20
Düsseldorf 20
Redondo Beach 19
Wilmington 19
Hanoi 18
Kochi 18
New York 17
Washington 17
Dallas 16
Des Moines 16
Menlo Park 15
Frankfurt am Main 13
Helsinki 13
Houston 13
Krefeld 12
Fairfield 11
Brooklyn 9
Milan 9
Montreal 9
Pune 9
Sofia 9
Tokyo 9
Warsaw 9
Woodbridge 9
Johannesburg 8
Rio de Janeiro 8
Chicago 7
Phoenix 7
Chennai 6
The Dalles 6
Ankara 5
Bhubaneswar 5
Council Bluffs 5
Falkenstein 5
Mexico City 5
San Francisco 5
Atlanta 4
Belo Horizonte 4
Brasília 4
Campinas 4
Fremont 4
Guangzhou 4
Haiphong 4
Kronberg 4
Lappeenranta 4
Lauterbourg 4
Nuremberg 4
Portsmouth 4
Querétaro 4
Redwood City 4
Stockholm 4
Thái Bình 4
Turku 4
Afragola 3
Amman 3
Baku 3
Bucharest 3
Calgary 3
Columbus 3
Da Nang 3
Dakar 3
Dublin 3
Esslingen am Neckar 3
Gangnam-gu 3
Hyderabad 3
Jakarta 3
Palermo 3
Paris 3
Porto Alegre 3
Quito 3
Roccasecca 3
Rome 3
Rottweil 3
San Giuseppe Vesuviano 3
Segrate 3
Shanghai 3
Tashkent 3
Abidjan 2
Aparecida de Goiânia 2
Asunción 2
Totale 2.311
Nome #
An indolent nasal form of primary cutaneous CD8-positive peripheral T-cell lymphoma not otherwise specified successfully treated with local radiation therapy- a new subtype? 150
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications 146
Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review 145
Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case 140
Generalized violaceous maculopapular rash and multiple verrucous nodules on the testes: a case of secondary syphilis misdiagnosed as lymphoma 123
A new dermoscopic pattern for chilblain-COVID-19–like skin lesions in adolescents 116
Apremilast efficacy and safety in elderly psoriasis patients over a 48-weeks period 115
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study 111
Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data 109
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge 107
Ciprofloxacin-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient 107
A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab 106
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 102
Erythrodermic Pityriasis Rubra Pilaris treatment: two case reports and literature review 102
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 101
Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II 101
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 100
Hereditary Angioedema Type III, Recurrent Pregnancy Loss and Heterozygous MTHFR Mutation 96
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 95
Anti‐interleukin‐23 for psoriasis in elderly: guselkumab, risankizumab and tildrakizumab in real world practice 92
Dermatophytid evaluated by in vivo reflectance confocal microscopy: a new approach? 92
Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study 92
Nail changes as manifestation of systemic disease in COVID‐19 infection 91
Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period 88
Letter to the editor regarding article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610." 88
Teledermatology: a useful tool also after Covid-19 era? 88
Real life efficacy and safety of secukinumab in elderly psoriasis patients over a 2-year period 87
Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5" 87
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study 86
Immune response to Covid‐19 mRNA vaccination in psoriasis patients undergoing treatment with biologics 85
A case of pediatric psoriasis successfully and rapidly treated with ixekizumab 84
Reply to “A case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption associated with Pfizer COVID ‐19 vaccination” by Manaa et al 82
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis? 82
Adalimumab biosimilar in a pediatric patient: clinical and in vivo reflectance confocal microscopy evaluation 79
A case of erythrodermic psoriasis successfully treated with guselkumab 79
A case of erythrodermic psoriasis successfully treated with apremilast 76
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 73
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-centre retrospective study in a real-life setting 70
Reply to ‘New‐onset cutaneous lichen planus triggered by COVID‐19 vaccination’ by Merhy et al 70
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 67
New frontiers in personalized medicine in psoriasis 66
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al 66
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge 63
Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series 61
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience 56
Giant basal cell carcinoma of the vulva successfully treated with Sonidegib 51
Treating psoriasis in the elderly: biologics and small molecules 48
A Case of Adult-onset Facial Cutaneous Mastocytoma: Clinical and Dermoscopic Findings 47
Topical oil formulation of plant extracts and vitamins as effective treatment for stretch marks and xerosis—An observational longitudinal study 47
Towards Personalized Medicine in Psoriasis: Current Progress 45
Paradoxical reactions to biologicals for psoriasis 39
Ixekizumab in scalp psoriasis: Clinical, dermoscopical, and in vivo reflectance confocal microscopy evaluation 38
Reply to "Routine re-screening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: a single-center retrospective cohort study" 38
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? 33
Totale 4.608
Categoria #
all - tutte 16.394
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.394


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021135 0 0 0 0 0 10 2 45 62 8 8 0
2021/2022277 1 7 0 14 15 6 8 17 63 41 24 81
2022/2023454 37 35 15 17 39 56 49 64 65 36 32 9
2023/2024397 24 46 33 40 38 88 6 51 2 8 48 13
2024/20251.699 74 24 7 14 52 108 153 93 141 259 636 138
2025/20261.610 334 243 281 246 443 63 0 0 0 0 0 0
Totale 4.608